Citations

Clear

3042 citation(s) found for "Kumar, S".

Evaluating Differences in the Proteome Within Extracellular Vesicles Between Pre- Malignant and Malignant Plasma Cell Disorders
Vanderboom, Patrick M. , Dasari, Surendra , Kapoor, Isha , Kumar, Shaji , N., K., Chawla, Yogesh, N, K Sreekumaran, Gonsalves, Wilson I.

Mayo Clinic

No container title available | November 30, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3673796/v1 Get It

Abstract Background: Precursor plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) always precede the development of active malignancies such as multiple myeloma (MM). There is a need for novel biomarkers to identify those patients with such precursor plasma cell disorders who rapidly progress to MM. Plasma-derived extracellular vesicles (EVs) may serve as a reservoir of potential biomarkers that can shed light on the pathogenesis and disease biology in MM. Methods: This study isolated small EVs (SEVs) and large EVs (LEVs) from the platelet-poor peripheral blood plasma of MGUS (n=9) and MM (n=12) patients using the size exclusion chromatography (SEC)-based method and evaluated their proteome using a label-free proteomics workflow. Results: In total, 2,055 proteins were identified in SEVs, while 2,794 proteins were identified in LEVs. The transferrin receptor (TFRC or CD71) protein was upregulated in both populations of EVs derived from MM patients compared to MGUS patients and was of prognostic significance. Similarly, three isoforms of serum amyloid A (SAA) protein, SAA1, SAA2, and SAA4, were also highly upregulated in SEVs within MM patients relative to MGUS patients. Finally, CD40 expression was also higher within the LEVs derived from MM patients than MGUS patients. Conclusions: This study demonstrates the feasibility of successfully isolating both SEVs and LEVs from the peripheral blood of patients with plasma cell disorders and quantifying protein biomarkers within these EVs that could be of prognostic and diagnostic interest.
Bridging the gap in BASCULE syndrome: A retrospective case series of a recently described clinical entity
Reinhart, Jacob P. , Kumar, Anagha , Casanegra, Ana I. , Rooke, Thom W. , Sartori‐Valinotti, Julio C. , Tollefson, Megha M. , Klaas, Kelsey , Davis, Dawn Marie R. , Kumar, Anagha Bangalore , Davis, Dawn M R , Casanegra, Ana I , Reinhart, Jacob

Mayo Clinic

Pediatric Dermatology | November 28, 2023 | Volume: 41 | Issue: 1 | Pages: 46-50

10.1111/pde.15470 | PMID 38014569 Get It

AbstractBackgroundBier anemic spots, cyanosis with urticaria‐like eruption (BASCULE) syndrome is a recently described entity with episodic urticarial lesions and white anemic halos on a background of erythrocyanosis, commonly affecting the lower extremities. Possible association with autonomic dysfunction remains poorly understood. Existing publications are limited, but the condition is suggested as highly underrecognized.ObjectiveTo further characterize clinical and epidemiologic data for BASCULE syndrome.MethodsWe performed an IRB‐approved retrospective chart review on patients with BASCULE syndrome evaluated at Mayo Clinic from April 2021 to November 2022.ResultsA total of 17 patients were identified (13 female, 4 male). Median age of onset was 12 years (range 9–17). Lower extremities were involved in all patients (17). Most patients were symptomatic with pruritus (8) or burning pain (8); three were asymptomatic. Triggers were standing (11), hot showers or hot environments (7), or no clear trigger (4). Autonomic dysfunction was present in 10 patients. Treatment responses were observed from propranolol (3) and high‐dose cetirizine (1).ConclusionNovel epidemiologic data from 17 pediatric and young adult patients with BASCULE syndrome further supports an association with autonomic dysfunction and suggests a higher prevalence than previously acknowledged.
Results of Patch Testing to Botanicals: Review of the Mayo Clinic Experience over 2 Decades (1997–2017)
Kumar, Anagha , Jin, Mauricio F. , Kunkel, Hilary, Sathe, Nishad, Hall, Matthew R. , Drage, Lisa A., Youssef, Molly J. , Yang, Yul W. , Yiannias, James A. , Killian, Jill M. , Davis, Mark D.P. , Youssef, Molly, Killian, Jill, Kumar, Anagha Bangalore

Mayo Clinic

Dermatitis® | November 27, 2023 | Volume: 35 | Issue: 1 | Pages: 43-48

10.1089/derm.2023.0109 | PMID 38011689 Get It

Abstract: Background: Botanicals are increasingly incorporated into skincare products. Although allergic contact dermatitis due to botanicals is recognized, data describing the prevalence of positive patch tests to botanicals are sparse. Objective: To report the Mayo Clinic experience of patch testing to selected botanical products in the standard, extended standard, fragrance, and plant series. Methods: IRB-approved retrospective study of the Mayo Clinic experience with patch testing to botanicals from 1997 to 2017. Results: In total, 12,169 people were patch tested to botanicals in the standard, extended standard, fragrance, and plant series; 4032 were men and 8137 were women. The mean age of the population tested was 54 (standard deviation 17.7) years. Almost 11% (1320/12,169) of the patch-tested population exhibited positive reactions to at least 1 botanical agent. Myroxylon pereirae resin 25% was the most common positive allergen in the series. Patients who had positive reactions to at least 1 botanical agent were more (19.8%) likely to have a positive reaction to at least 1 additional botanical than those patients who did not have any positive tests. Most patients presented with generalized involvement (334) or involvement of the hands (284) or face (232). Conclusion: Physicians should be aware of the high prevalence of allergic contact dermatitis and patch test positivity associated with botanical products.
6 N‐Cyclohexyladenosine Suppresses Shivering in Anesthetized Swine
Drew, Kelly L. , Kumar, Matthew , Tøien, Øivind

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 31 | Issue: S1 | Pages: No page available

10.1096/fasebj.31.1_supplement.lb607 Get It

Shivering compromises post‐operative recovery and patient comfort. Shivering is also an impediment to targeted temperature management (TTM), now standard of care for cardiac arrest. Without an effective drug to suppress shivering (referred to here as a thermolytic) high cost and difficulty of temperature management is restricting access to TTM outside of large hospitals and for conditions such as stroke. A more efficacious thermolytic is needed for post‐operative control of shivering and to improve patient comfort during TTM. Our prior work in rats, based on strong scientific premise from the study of hibernating animals, suggests that stimulating CNS A 1 adenosine receptors (A 1 AR) by combining the A 1 AR agonist 6 N cyclohexyladenosine (CHA) with the peripherally acting adenosine receptor antagonist 8‐(p‐sulphophenyl)theophylline (8‐SPT) will provide an effective means to control shivering. This approach works in rodents however, thermolytic efficacy has not been demonstrated in a larger mammal that, like humans, depends primarily on shivering thermogenesis to maintain body temperature. To assess the thermolytic efficacy of CHA in 50–55 kg swine, a species that lacks brown adipose tissue, three pigs were anesthetized with Telazol/Xylazine, propofol, or isoflurane and cooled to a target body temperature of 32 to 34°C with a water blanket set to 4°C. Probes measured core body temperature at the tympanum, lower esophagus, rectum and bladder. Electrocardiography, pulse oximetery and arterial blood pressure were monitored. Shivering was measured by respirometry and by a qualitative visual scale. When shivering was noted, CHA was administered (bolus, 4.2mg; infusion,113μg/kg/h). 8‐SPT (bolus, 186mg), atropine (bolus, 0.5mg) or epinephrine (bolus, 100μg) was then given IV to reverse bradycardia and hypotension. At completion, animals were euthanized and tissues collected for histopathology. Results show that CHA inhibits shivering and that 8‐SPT restores blood pressure and heart rate without reversing the thermolytic effect of CHA. No histopathology was noted. In conclusion, CHA is an effective thermolytic in swine. Support or Funding Information This work was supported by Be Cool Pharmaceutics LLC and the Mayo Clinic
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them
Rees, Matthew J. , Kumar, Shaji , Rees, Matthew James

Mayo Clinic

Leukemia & Lymphoma | November 21, 2023 | Volume: 65 | Issue: 3 | Pages: 287-300

10.1080/10428194.2023.2284088 | PMID 38354090 Get It

Postoperative Neurological Deficits with Incidence and the Various Arterial Territories Involved in Patients Undergoing Congenital Cardiac Surgery: A Single-center Analysis
Rahul, Kumar , Kumar, Sarvesh , Kaushik, Karan , Kumar, Satish, Garg, Pankaj , Aggarwal, Vishal, Tewarson, Vivek

Mayo Clinic

Research in Cardiovascular Medicine | November 21, 2023 | Volume: 12 | Issue: 3 | Pages: 84-88

10.4103/rcm.rcm_40_23 Get It

Introduction: The incidence and pattern of neurological complications after congenital cardiac surgery have been changing over the years due to improvement in surgical technique and perioperative management. The aim of this study was to evaluate the incidence and pattern of neurological injury in our institute. Materials and Methods: We retrospectively reviewed all pediatric patients who underwent noncontrast computed tomography of the brain for suspected postoperative neurological injury occurring during the 1 st week after pediatric cardiac surgery between April 2016 and February 2020. We identified neurological injury as patients having ischemic infarct and intracranial hemorrhage. Results: A total of 2971 pediatric cardiac surgeries were performed at our institute. Sixty-seven patients (2.25%) developed neurological injury. Fifty-five patients (82%) developed ischemic infarct while 12 patients (18%) had intracranial hemorrhagic. Pattern of ischemic infarct included global hypoxic injury in 30 patients (54.5%), posterior cerebral artery territory in 9 patients (16.3%), middle cerebral artery territory in 8 patients (14.5%), multiterritory involvement in 5 patients (9.0%), and anterior cerebral artery territory in 3 patients (5.4%). In patients with intracranial hemorrhage, 5 patients (7.4%) developed subarachnoid hemorrhage (SAH), 4 patients (5.9%) developed subdural hemorrhage, and 3 patients (4.4%) developed intraparenchymal hemorrhage. Conclusions: Neurological complication accounts for significant morbidity and mortality after congenital cardiac surgery. In our study, ischemic infarct accounted for 82% cases. In ischemic infarct, global ischemia was the most common type and carried high risk of mortality. In hemorrhage group, SAH was the most common finding. Nevertheless, the aim of this study was to characterize the current incidence of acute clinically evident neurologic complications in children undergoing congenital cardiac surgery in a tertiary hospital, although acute neurologic morbidity appears to be appreciably lower than in the past at our institution.
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
Plesner, Torben , Kumar, Shaji , Hulin, Cyrille , Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand , Pei, Huiling , Kaila, S., Matt, K., Gries, Katharine S. , Carson, Robin, Borgsten, F., Facon, Thierry T.F. , Usmani, Saad Z. , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Roussel, Murielle , Jaccard, Arnaud , Karlin, Lionel , Chari, Ajai , Gupta, Neeraj , Matt, K., Weisel, Katja C , Perrot, Aurore

Mayo Clinic

HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 18-19

10.1097/01.hs9.0000936192.21618.f2 Get It

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
Kumar, Shaji , Facon, T., Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, F., Weisel, Katja C , Moreau, Philippe , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Raje, Noopur , Frenzel, Laurent , Usmani, Saad Z.

Mayo Clinic

HemaSphere | November 16, 2023 | Volume: 7 | Issue: S2 | Pages: 14-15

10.1097/01.hs9.0000936164.84357.ed Get It

Daptomycin‐induced hyperkalemia: A case report and brief description of mechanism
Errabelli, Praveen , Lathiya, Maulik , Errabelli, Praveen Kumar , Lathiya, Maulik K , Roy, Sasmit

Mayo Clinic

Clinical Case Reports | November 13, 2023 | Volume: 11 | Issue: 11 | Pages: No page available

10.1002/ccr3.8188 | PMID 37965183 Get It

Key Clinical MessageDaptomycin causes serious side effects like rhabdomyolysis at high doses. At lower doses it can cause isolated hyperkalemia without frank rhabdomyolysis. Checking BMP along with CK helps taking timely measures to prevent adverse consequences.AbstractHyperkalemia is a common yet challenging clinical condition faced daily by physicians worldwide. Accurate etiology and timely management are paramount in correcting this preventable yet life‐threatening electrolyte imbalance. Very seldom has Daptomycin been implicated as a culprit for hyperkalemia. We present one such unique case where a low dose of Daptomycin led to hyperkalemia, and timely identification improved patient outcomes. We present a 69‐year‐old woman with multiple comorbidities admitted to the intensive care unit to manage diabetic ketoacidosis and sepsis. She developed acute kidney injury due to intravenous contrast, volume depletion, and obstructive uropathy. Interestingly although initially normokalemic, as her renal function started improving with sound urine output, she developed recurrent hyperkalemia, which required medical management. The etiology of hyperkalemia was initially unclear, but on closer review, it was discovered that Daptomycin was the potential culprit. Although case studies with high‐dose Daptomycin causing rhabdomyolysis and hyperkalemia have been reported, low‐dose Daptomycin causing hyperkalemia without rhabdomyolysis has never been reported, bringing forth the uniqueness of our article.
TMET-02. CLINICAL EFFICACY OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IS DRIVEN BY DISRUPTION OF INTEGRATED METABOLIC AND EPIGENETIC PATHWAYS
Venneti, Sriram , Sweha, Stefan R. , Pun, Matthew , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Garton, Hugh , Franson, Andrea , Schwartz, Jonathan , Mottl, Sophie L. , Cartaxo, Rodrigo T. , John, Vishal , Messinger, Dana , Judkins, Alexander R. , Wahl, Daniel , Lyssiotis, Costas A. , Alonso, Martha, Cain, Jason E. , Jiang, Li , Mody, Rajen , Kline, Cassie , Mueller, Sabine , Allen, Joshua E. , Franson, Andrea , Lyssiotis, Costas A , Kawakibi, Abed Rahman , Ji, Sunjong , Waszak, Sebastian M. , Mota, Mateus , Deogharkar, Akash , Chung, Chan , Tarapore, Rohinton S. , Ramage, Samuel , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Jain, Rajan , Qin, Tingting , Peterson, Erik, Sajjakulnukit, Peter , Nava, Daniel de la , Duchatel, Ryan J , Dun, Matthew D , Filbin, Mariella G , Zhao, Lili , Kumar-Sinha, Chandan , Chinnaiyan, Arul , Kurokawa, Ryo , Pratt, Drew , Yadav, Viveka Nand , Grill, Jacques , Resnick, Adam , Nazarian, Javad , Odia, Yazmín , Gardner, Sharon L , Koschmann, Carl

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v272-v272

10.1093/neuonc/noad179.1046 Get It

Abstract H3K27M-mutant diffuse midline glioma (DMG) patients have no proven effective therapies beyond radiation. ONC201, a mitochondrial protease ClpP agonist, has recently demonstrated efficacy in these patients, but the mechanism behind this remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue samples from patients treated in two completed multi-site clinical studies (n=71). Patients treated with ONC201 monotherapy following initial radiation but prior to recurrence (n=35) demonstrated a median overall survival of 21.7 months and a median progression-free survival of 12.2 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle-related genes in baseline tumor sequencing. Similar survival benefits were observed using in utero electroporation and orthotopic mouse models of H3K27M-DMG (median 107 versus 77 days [p=0.02] and median 97 versus 141 days [p=0.004], respectively). Integrated transcriptomic and metabolomic analysis of ONC201-treated H3K27M-DMG cells revealed downregulation of TCA cycle, glycolysis, and pyruvate metabolism genes, most notably oxoglutarate dehydrogenase (OGDH), and concomitant changes in levels of associated metabolites including ɑ-ketoglutarate (ɑ-KG). Interestingly, L-2-hydroxyglutarate (L-2HG), a known inhibitor of the Jumonji C domain family of histone lysine demethylases, was also increased. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuro-glial differentiation genes. Genetic knockdown of OGDH recapitulated ONC201-mediated increases in H3K27me3. In contrast, genetic knockdown of ClpP or lactate dehydrogenase A or overexpression of L-2-hydroxyglutarate dehydrogenase (L-2HGDH), but not D-2HGDH, abrogated ONC201-mediated increases in H3K27me3, demonstrating that ONC201 induces the production of L-2HG in H3K27M-DMG cells leading to increased H3K27me3. Overall, our data demonstrates the efficacy of ONC201 in H3K27M-mutant DMG and supports ONC201 as the first monotherapy to improve outcomes in patients with H3K27M-mutant DMG for whom few therapeutic options currently exist. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction.